Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

Oxaliplatin

For research use only.

Catalog No.S1224 Synonyms: L-OHP

100 publications

Oxaliplatin Chemical Structure

CAS No. 61825-94-3

Oxaliplatin (L-OHP) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Oxaliplatin has been cited by 100 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin (L-OHP) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[9]
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Caco2 MW\GeY5kfGmxbjDBd5NigQ>? MmeyN|AwOTBywrFOwG0> MoG3NVbDqGh? MkjOSG1UVw>? NWDrbZVt[WO2aY\heIV{KE6{ZkK= M3LGWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW2OFE2Lz5{NEW1OlQyPTxxYU6=
Caco2  MkjFSpVv[3Srb36gRZN{[Xl? M2\YUFMwOTBxM{Cg{txO MkXyNVYhcA>? M1i2dWROW09? NF3NfFJqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCDS2KxR|EtKE6TT{GsJGhQNTFuIF3SVFItyqCjbnTNVnA{yqCmb4PlMYRmeGWwZHXueIx6 NYLVOnlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVY1OTVpPkK0OVU3PDF3PD;hQi=>
Caco2  NWHpSWhUTnWwY4Tpc44hSXO|YYm= MX:zNOKh|ryP MoXnNlQhcA>? NX:5fVRlTE2VTx?= MknlbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDIU{0yNCCDS2KxR{wh[W6mIF7RU|E> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3NkSxOUc,OjR3NU[0NVU9N2F-
SW620 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv2T|EyOC15MDDt[{9N NIfWenAzPC92OD:3NkBp NXjTTGpCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= Mk\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NE[zNFUoRjJ2NkS2N|A2RC:jPh?=
SW480  M2K0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nP[lQ5KGkEoB?= M13KdWlEPTB;MkCuPEB2\y:vTB?= M3j5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{KwOlc2Lz5{NEeyNFY4PTxxYU6=
HCT116 MUXGeY5kfGmxbjDBd5NigQ>? MXiyM|UhyrWP NVnvdocyOjRxNEigbC=> NHLvbWZ{fXCycnXzd4V{KHO3co\peolvKG2UTlGg[ZhxemW|c3nvci=> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4MUSxNUc,OjR5NkG0NVE9N2F-
HT-29 NHHwZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K1UVHDqM7:TR?= NV\iNYRoOC15MjDo MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MkKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 NWHIVWNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnNNeKh|ryP NGDYeIExNTd{IHi= NYrlfGZVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? Mk\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
HUVEC NEPYSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjvb3BKSzVyPUGxMlMxyqEEsdMgNU4xOiEQvF2= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
HEK293 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXNWWxKSzVyPUiuPFLDqMLzwrC1MlU6KM7:TR?= NGPGOpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO|Q1QCd-MkWzNFc1PDh:L3G+
HT-29 NVPpfJY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnOzTWM2OD53MDFOwG0> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
HCT-116 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:0d|VvUUN3ME22MlI1yqEEsdMgNk46PyEQvF2= NWK0V5hoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
MCF-7 NUeyc45JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe3d3h7UUN3ME2xOE4zPMLiwsJCpFEvQDJizszN NU[5T5U4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
HepG2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3faR2lEPTB;MUSuNlTDqMLzwrCxMlgzKM7:TR?= NF;ocnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO|Q1QCd-MkWzNFc1PDh:L3G+
A549 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTVzLkC4xsDDucLiMUCuPVYh|ryP NVjlO2tCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
SGC7901 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJzLkezxsDDucLiMz6wPEDPxE1? MkXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
COC1 M{LZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHZTWM2OD12Nj6yNOKhyrIEoEOuNVQh|ryP MlS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
HCT116  NGO0VmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUO3NkBpyqB? NEH5V5lKSzVyPU[uNlPDuTBwN{WgxtVoN22O MoLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|NkC2N|EoRjJ3M{[wOlMyRC:jPh?=
SW480 Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV23NkBpyqB? MUfJR|UxRTFyLkhCtVIvOjZiwsXnM41N NGe0emQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NFY{OSd-MkWzOlA3OzF:L3G+
MIAPaCa-2 MUXGeY5kfGmxbjDBd5NigQ>? NHrueoszPeLCidM1US=> MkDTNlQwPDhiaB?= M2C0dIlv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg NWf1PZNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
Panc-1 M3jRe2Z2dmO2aX;uJGF{e2G7 NFjCNXMzPeLCidM1US=> M4HDblI1NzR6IHi= NGLEPWFqdmS3Y3XzJINt\WG4YXflJI9nKFCDUmCsJINie3Cjc3WtPUwh[2G|cHHz[U05KGGwZDDjZZNx[XOnLURCpC=> MnOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
MIAPaCa-2 MVvBdI9xfG:|aYOgRZN{[Xl? NXTEWYdOOjYkgJpCuW0> NHX0O|gzPCCq NH\yOplqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
Panc-1 M4P2TmFxd3C2b4Ppd{BCe3OjeR?= M3W5WlI26oDLwsXN MkX6NlQhcA>? MV7pcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
HPDE NI\CXWVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NInYWY0zPS93MDFOwG0> NYXTRlVuOjRxNEigbC=> NGm2T5FqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? M4G5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
SW1990 MoX4R4VtdCCYaXHibYxqfHliQYPzZZk> MYmyOU82OCEQvF2= Mo\5NlQwPDhiaB?= MnfJbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MkjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
MIAPaCa-2 MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHrvd|gzPS93MDFOwG0> MVqyOE81QCCq Ml7GbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MlLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
Panc-1 NEnxeGRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NILZ[JozPS93MDFOwG0> MWmyOE81QCCq MoXabY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC M33ublxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
A549/CDDP MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjHcoRKSzVyPUG4MlYhyrFiMT6yJO69VQ>? NGflSYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVI1Oyd-MkW2NlUzPDN:L3G+
A549 M3TaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnGTWM2OD13LkigxtEhOC54IN88US=> NYj4W3ZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlUzPDNpPkK1OlI2OjR|PD;hQi=>
SW480 M{j1UmZ2dmO2aX;uJGF{e2G7 MoXFNVDjiIoEtXevcYw> NF\3OIczPOLCiXi= M4jz[oVvcGGwY3XzJINmdGy3bHHyJIF2fG:yaHHnbYMh\my3eB?= M4HyVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
SW620 MXrGeY5kfGmxbjDBd5NigQ>? MkDRNVDjiIoEtXevcYw> NUf5d3pbOjUkgJno M37yNoVvcGGwY3XzJINmdGy3bHHyJIF2fG:yaHHnbYMh\my3eB?= NHnCR5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW480 MWXGeY5kfGmxbjDBd5NigQ>? Mk\zNVDjiIoEtXevcYw> NWDGfZg5OjUkgJno MorJbY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>? NHzCdoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW620 MYfGeY5kfGmxbjDBd5NigQ>? MmLpNVDjiIoEtXevcYw> NH;kVIYzPOLCiXi= NE\6VFlqdmO{ZXHz[ZMhVEN|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUSyNEc,OjV5NEm0NlA9N2F-
HT-29 NXjIW4dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfy[2ZKSzVyPUWuNlIh|ryP NH[yOGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
SNU-175 NWjuflM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPmR3E5UUN3ME2xMlUyKM7:TR?= M{TwdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
COLO-320DM NYqyTWt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTVwM{ig{txO NXLyWopjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlE1PzlpPkK1O|YyPDd7PD;hQi=>
DLD-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vidmlEPTB;OD62OUDPxE1? MmnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O|koRjJ3N{[xOFc6RC:jPh?=
DiFi NHvxRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzReIc6UUN3ME2xNE46PSEQvF2= NH6yW5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
HCT-15 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP1TWM2OD16Lk[0JO69VQ>? Mnf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O|koRjJ3N{[xOFc6RC:jPh?=
SCM-1 NYW1W|dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXkZ3E5UUN3ME2xO{42KM7:TR?= MmL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
TMK-1 NWnze49mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi5TWM2OD1{Mj62JO69VQ>? MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd6OUC1O{c,OjV5OEmwOVc9N2F-
MKN-45 MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF2LkCg{txO MoLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
AGS MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnmSHlHUUN3ME2xNE43KM7:TR?= Mlf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
S3 NH;BOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonqTWM2OD13Mz61JOKyKDFwNTFOwG0> NIDze3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwNVAxPyd-MkW4NFExODd:L3G+
SiHa NWHh[HlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjLS4hKSzVyPUCuPEDDuSByLkGg{txO MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyMUCwO{c,OjV6MEGwNFc9N2F-
HT-29 NUD4NJZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHZTWM2OD1|NT62JO69VQ>? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByM{C4OUc,OjZyMEOwPFU9N2F-
DLD-1 M{P6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rsNGlEPTB;M{KuNkDPxE1? M37Ye|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MECzNFg2Lz5{NkCwN|A5PTxxYU6=
HT29 NYDkelI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnvTWM2OD14MzFOwG0hyrFiMUi= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNEC4OEc,OjZyMESwPFQ9N2F-
MC38 NHmzR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPIZWxiUUN3ME2yN{DPxE1iwsGgNi=> NV\IdmpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFQxQDRpPkK2NFA1ODh2PD;hQi=>
SW620 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jKN2lEPTB;Mz62PEDPxE1? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
SW480 NYPHOWpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HYWmlEPTB;Mj64OkDPxE1? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
RKO MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwMkOg{txO MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
LoVo M3TPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwMjFOwG0> M2K3elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
KM12 MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjVTWM2OD12LkO3JO69VQ>? NGDHR409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
HCT116p53- M3LVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DMbmlEPTB;MT6wPEDPxE1? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
HCT116 NWHNdFZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXMTWM2OD1zLkC0JO69VQ>? M1L2bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
HCT15 M4Plbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nMR2lEPTB;MT60N{DPxE1? MnX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
HT29 MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJwNkmg{txO NGLhXIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
DLD1 M3f2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK3bFI2UUN3ME2yMlAyKM7:TR?= NE\GS5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
Colo205 NFjYOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTNwM{Og{txO M2fPUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
BE MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH64UWVKSzVyPUOuN|Mh|ryP M2XQUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
CT26  MoPyR4VtdCCYaXHibYxqfHliQYPzZZk> M2O2eFQhdU1? NGnpbHc1QCCqwrC= MX;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlidH:gOVMvOiV? NE\w[WE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|AyOid-Mk[xN|cxOTJ:L3G+
CT26  NVG1d5h3TnWwY4Tpc44hSXO|YYm= M3Hp[|QhdU1? M3v6OlQ5KGkEoB?= Mn3NbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDheZRweGijZ4mtdoVt[XSnZDDwdo91\Wmwczygd5VkcCCjczDMR|MuUUluIFLlZ4xqdjFiYX7kJGFVTzV? NUnpfpFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|cxOTJpPkK2NVM4ODF{PD;hQi=>
CT26  MYfGeY5kfGmxbjDBd5NigQ>? MnjmOEBuVQ>? M1TXeVQ5KGkEoB?= MoHFbY5lfWOnczDheZRweGijZ4m= MnnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{ewNVIoRjJ4MUO3NFEzRC:jPh?=
SK-OV-3 MnLMSpVv[3Srb36gRZN{[Xl? MUe1NEDPxE4EoB?= NF\kb5M1QCCqwrC= MkDTdJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm|aYO= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
OVCAR-5 NH3PW5pHfW6ldHnvckBCe3OjeR?= M{DBblIxKM7:TdMg NELFdowzPGh? Ml;hdJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm|aYO= M2DMb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
PA-1 Mmr5SpVv[3Srb36gRZN{[Xl? M2DxPVExKM7:TdMg M4nSeVI1cA>? MlnUdJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm|aYO= MnXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
SK-OV-3 MWPGeY5kfGmxbjDBd5NigQ>? MkfvOVAh|ryP MmXjPVYhcA>? Mk\keZAuemWpdXzheIV{KHSqZTDzeJJme3NibHnnZY5leyCob4KgUmsh[2WubD3hZ5RqfmG2aX7nJJJm[2WydH;yd{BidmRiVGLBTWwhemWlZYD0c5J{ MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
OVCAR-5 NV3BOG5sTnWwY4Tpc44hSXO|YYm= MlzrN|Ah|ryP MUC0PIg> MXv1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> NWrQepViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
PA-1 NFnvSWNHfW6ldHnvckBCe3OjeR?= MnfYNVAh|ryPwrC= NEKzNlg1QGh? NVfrb45YfXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
SK-OV-3 MlHuSpVv[3Srb36gRZN{[Xl? NHzaXmg2OCEQvF2= NV[1V3gxQTZiaB?= MVf0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= NVvtUG9pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
OVCAR-5 M1TadWZ2dmO2aX;uJGF{e2G7 MlXyN|Ah|ryP MUK0PIg> M{LVNpRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> NXzOOZZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
PA-1 NH;Wb2JHfW6ldHnvckBCe3OjeR?= NUjhS4tNOTBizszNxsA> MX[yOIg> MUX0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
SK-OV-3 NVTvO4tyS2WubDDWbYFjcWyrdImgRZN{[Xl? M4jKdFAuOTByIN88US=> NEfqPIkzPC92OD:3NkBp Ml\5bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
OVCAR-5 NUP6W|d7S2WubDDWbYFjcWyrdImgRZN{[Xl? NHPHZmoxNTZyIN88US=> NH3MfVAzPC92OD:3NkBp M2rQWYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M2H2OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
PA-1 NIPBdJJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEfieokxNTJyIN88US=> M3;QUFI1NzR6IHi= MXnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Mmq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
HCT116 NEnRV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwNEJCpOKyyqByLkCyJO69VQ>? M13QSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUS4OVk3Lz5{NkG0PFU6PjxxYU6=
HT29 NWXlOpFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3We4VTUUN3ME2wMlg5yqEEsdMgNE4zKM7:TR?= NHm0TFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG0PFU6Pid-Mk[xOFg2QTZ:L3G+
SNU-387 MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;3cohKSzVyPUK1xsDDucLiMj63JO69VQ>? NIS1fVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
SNU-475 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWmyR3pzUUN3MP-8olMxKM7:TR?= NIrpT2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
Hep-G2 MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj2UldKSzVyPUGzMlHDqMLzwrCxMlYh|ryP MmDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNkC0NlkoRjJ4MU[wOFI6RC:jPh?=
SNU-398 M1jtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zLcWlEPTB;Nj61xsDDucLiMT6xJO69VQ>? NHTHfW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
LoVo  MmLQSpVv[3Srb36gRZN{[Xl? NFe1fXUyNzVizszN MWmyOE81QCCq MkCzbY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?= NUTYZ4l7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFg2OjNpPkK2NlA5PTJ|PD;hQi=>
HCT116 p53+/+ M1rKO2Z2dmO2aX;uJGF{e2G7 M3LmblEwPSEQvF2= NE\VXJUzPC92ODDo NFS1dYlqdmS3Y3XzJJRz[W6|Y4LpdJRqd26jbDDy[ZBz\XO|aX;uJI9nKESXVD3O MojSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MEi1NlMoRjJ4MkC4OVI{RC:jPh?=
MDA-MB-231 M{S4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTGNGt1UUN3ME2yN{4yKMLzIECuNUDPxE1? NUDOeGJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNVE2QTFpPkK2NlEyPTlzPD;hQi=>
MCF-7 M{TnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XVWmlEPTB;MUWuOEDDuSByLkOg{txO M2r0d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGxOVkyLz5{NkKxNVU6OTxxYU6=
SK-BR-3 M1vQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXsN4pKSzVyPUOxMlAhyrFiMD6xJO69VQ>? MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJzMUW5NUc,OjZ{MUG1PVE9N2F-
LoVo NIDhZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT0PHBlPDhiaNMg NV3FPWp4UUN3ME25OE45OyEQvF2= M{D0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mk[5O|U6Lz5{NkK2PVc2QTxxYU6=
HCT116 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjnToU1QCCqwrC= NGH6Rm5KSzVyPUGxMlg3KM7:TR?= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ4OUe1PUc,OjZ{Nkm3OVk9N2F-
SW480 M1rtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTYOXRmPDhiaNMg NV3kR2pvUUN3ME2xMlg4KM7:TR?= MnvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{Nkm3OVkoRjJ4Mk[5O|U6RC:jPh?=
CaES-17 MYPDfZRwfG:6aXPpeJkhSXO|YYm= NVXkN4ZQOOLCk{G2NOKh|ryP M{D4U|Q5yqCq M1nYPWlEPTB;NT61xsDDucLiMD6yJO69VQ>? NVz4R4JyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0O|Q3QTNpPkK2OFc1Pjl|PD;hQi=>
HKESC-2 MVXDfZRwfG:6aXPpeJkhSXO|YYm= M1TlZlDjiJNzNkFCpO69VQ>? NVrIZpp2PDkEoHi= NXHmbY9qUUN3ME21MljDqMLzwrCwMlUh|ryP MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
VEGFR-1 / NRP-1 ; 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. 

p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min.

p-Src(Y418) / p-FAK(Y861) ; 

PubMed: 19383922     


Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ

18790786 19383922
Immunofluorescence
E-cadherin / Vimentin; 

PubMed: 30787271     


Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells.

ATXN2L / G3BP1; 

PubMed: 30787271     


Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules. 

30787271
Growth inhibition assay
Cell viability ; 

PubMed: 28339092     


Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations. 

28339092
In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:

[4]

- Collapse
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control


    (Only for Reference)
Animal Research:

[6]

- Collapse
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage 2 years 4°C(in the dark) powder
1 week 4°C(in the dark) in solvent
Synonyms L-OHP
Smiles C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04158349 Recruiting Drug: Oxaliplatin|Drug: mFOLFIRI Colorectal Cancer|Appendiceal Cancer|Peritoneal Carcinoma University of Utah June 11 2020 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID